Synairgen PLC OMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBP 0.07
- Day Range
- GBP 0.07–0.07
- 52-Week Range
- GBP 0.03–2.84
- Bid/Ask
- GBP 0.00 / GBP 0.00
- Market Cap
- GBP 14.00 Mil
- Volume/Avg
- 0 / 1,061
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 27
- Website
- https://www.synairgen.com
Valuation
|
Metric
|
OMY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
OMY
Financial Strength
|
Metric
|
OMY
|
|---|---|
Quick Ratio | 6.77 |
Current Ratio | 6.77 |
Interest Coverage | — |
Quick Ratio
OMY
Profitability
|
Metric
|
OMY
|
|---|---|
Return on Assets (Normalized) | −37.93% |
Return on Equity (Normalized) | −44.52% |
Return on Invested Capital (Normalized) | −46.61% |
Return on Assets
OMY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rcmfnsbtcs | Vqzc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xznlrypd | Vrlwp | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qfbzxdrt | Xypzn | $97.8 Bil | |
MRNA
| Moderna Inc | Gpsnylykb | Kqv | $41.3 Bil | |
ARGX
| argenx SE ADR | Zkhsdjsbd | Xdm | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mgbcgmk | Trz | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pfncyjj | Gpmpwkf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fppqmsvmy | Qlsvfz | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pwpjdkqsr | Pfxwg | $12.5 Bil | |
INCY
| Incyte Corp | Nltsbmcb | Zsflm | $11.6 Bil |